Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Siguret

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Thrombosis and Haemostasis|November 1, 2013
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT studyIsabelle Gouin-Thibault, Claire Flaujac, Xavier Delavenne, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2011
Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypesC Moreau, E Pautas, I Gouin-Thibault, et al.
La Revue De Medecine Interne|December 31, 2013
[Relationship between maintenance dosages of fluindione (Préviscan) and warfarin (Coumadin) for patients 70 years and older]É Pautas, I Peyron, I Gouin-Thibault, et al.
Angiology|December 2, 1999
Ruling out acute deep vein thrombosis by ELISA plasma D-dimer assay versus ultrasound in inpatients more than 70 years oldA F Le Blanche, V Siguret, C Settegrana, et al.
Human Genetics|February 1, 1994
A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWDV Siguret, J M Lavergne, G Chérel, et al.
Thrombosis and Haemostasis|December 29, 2000
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 daysV Siguret, E Pautas, M Février, et al.
Journal of Thrombosis and Haemostasis : JTH|January 30, 2015
Multimodal assessment of non-specific hemostatic agents for apixaban reversalA-C Martin, I Gouin-Thibault, V Siguret, et al.
European Journal of Human Genetics : EJHG|January 1, 1993
Haemophilia B due to a de novo insertion of a human-specific Alu subfamily member within the coding region of the factor IX geneD Vidaud, M Vidaud, B R Bahnak, et al.
British Journal of Haematology|December 1, 1988
Identification of a CpG mutation in the coagulation factor-IX gene by analysis of amplified DNA sequencesV Siguret, S Amselem, M Vidaud, et al.
Blood|February 1, 1994
Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand diseaseA S Ribba, O Christophe, A Derlon, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Thrombosis and Haemostasis|November 1, 2013
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT studyIsabelle Gouin-Thibault, Claire Flaujac, Xavier Delavenne, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2011
Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypesC Moreau, E Pautas, I Gouin-Thibault, et al.
La Revue De Medecine Interne|December 31, 2013
[Relationship between maintenance dosages of fluindione (Préviscan) and warfarin (Coumadin) for patients 70 years and older]É Pautas, I Peyron, I Gouin-Thibault, et al.
Angiology|December 2, 1999
Ruling out acute deep vein thrombosis by ELISA plasma D-dimer assay versus ultrasound in inpatients more than 70 years oldA F Le Blanche, V Siguret, C Settegrana, et al.
Human Genetics|February 1, 1994
A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWDV Siguret, J M Lavergne, G Chérel, et al.
Thrombosis and Haemostasis|December 29, 2000
Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 daysV Siguret, E Pautas, M Février, et al.
Journal of Thrombosis and Haemostasis : JTH|January 30, 2015
Multimodal assessment of non-specific hemostatic agents for apixaban reversalA-C Martin, I Gouin-Thibault, V Siguret, et al.
European Journal of Human Genetics : EJHG|January 1, 1993
Haemophilia B due to a de novo insertion of a human-specific Alu subfamily member within the coding region of the factor IX geneD Vidaud, M Vidaud, B R Bahnak, et al.
British Journal of Haematology|December 1, 1988
Identification of a CpG mutation in the coagulation factor-IX gene by analysis of amplified DNA sequencesV Siguret, S Amselem, M Vidaud, et al.
Blood|February 1, 1994
Discrepancy between IIA phenotype and IIB genotype in a patient with a variant of von Willebrand diseaseA S Ribba, O Christophe, A Derlon, et al.
Pageof 5